IL-MAY-RIVER-CAPITAL
26.4.2022 17:59:04 CEST | Business Wire | Press release
May River Capital , a Chicago-based private equity firm focused on lower middle market industrial growth companies, announced today the creation of Automated Handling Solutions (www.automatedhandlingsolutions.com ), a newly established platform offering highly engineered material handling equipment and automation solutions. The platform was formed through the combination of two specialty conveying and material handling businesses: Spiroflow, a global manufacturer of material handling equipment and provider of control systems integration, and Cablevey Conveyors, a market leading manufacturer of patented tubular drag conveying systems for food and beverage and high value industrial applications. Together, the combined companies will offer a differentiated and comprehensive suite of material handling equipment and industrial automation solutions to marquee customers globally.
“We are thrilled to welcome Spiroflow and Cablevey to the May River portfolio. We see an extraordinary opportunity to invest and grow these market-leading brands under one platform. With these foundational assets, we expect to further accelerate the profitable growth both Spiroflow and Cablevey have seen during the past several years,” said May River Partner, Steve Griesemer. “The specialty conveying sector is a high growth segment serving attractive end markets. Under the new platform, Cablevey and Spiroflow are uniquely positioned to serve this growing demand and build upon their track records of delivering innovative solutions to global customers.”
Founded in 1971 by Michel Podevyn and based in Monroe, North Carolina, Spiroflow offers one of the most comprehensive lines of handling equipment and complementary automation solutions in the industry, including flexible screw conveyers, bulk material filling and discharging equipment and integrated control solutions. Spiroflow was a pioneer and early innovator in flexible screw conveying. During its history, the company has built a strong reputation as a provider of precision material handling equipment used in high value applications in markets such as food and beverage, pharmaceutical, nutraceutical and specialty chemical end markets.
Through the leadership of Podevyn and CEO and Co-Chairman Jeff Dudas, Spiroflow has achieved significant recent growth in both the US as well as the UK, where the business was founded and still has a key facility. With installations in more than 50 countries, the company’s technology is known for its safety, efficiency and reliability, serving some of the most demanding material handling applications.
“We’ve come a long way during the past 50 plus years, as we’ve built a company that has become an important and reliable partner to our customers,” said Podevyn. “ We could not be more excited for the Spiroflow team to take the company to the next level through its new partnership with May River Capital.”
“With the additional financial and operational resources May River brings, we are excited to continue to invest in the business and drive growth. We believe this new partnership will further our track record of innovation and expansion that has served our customers, employees and the entire Monroe, North Carolina, and Clitheroe, UK communities well during the past several decades,” said Spiroflow CEO and Co-Chairman Jeff Dudas. Dudas will continue with Spiroflow as interim CEO, focusing on advancing growth-oriented initiatives through his deep network of customer and industry relationships.
“Spiroflow’s portfolio of conveying, storage, automation integration and system designs, combined with a North American and European presence, have positioned the company perfectly to catalyze this new platform’s growth,” said May River Executive Resource Group member Brad Sterner, who is acting CEO of Cablevey and will become Executive Chairman of AHS. “We will leverage May River’s ownership of both the Advanced Material Processing (AMP) process equipment platform and AHS to drive continued market share gains in our served global, high growth end markets of food, pharmaceutical, nutraceutical, chemical and general industrial sectors.”
Winston & Strawn served as legal counsel to May River. BDO, Capital Advisors, LLC served as financial advisor, while Shumaker, Loop & Kendrick, LLP served as legal counsel to Spiroflow and its shareholders.
About May River Capital
May River Capital is a Chicago-based private equity firm focused on investing in lower middle-market, industrial growth companies. May River Capital invests in high-quality industrial growth businesses, including precision manufacturing, engineered products and instrumentation, specialized industrial services, and value-added industrial distribution services. For more information, please visit www.mayrivercapital.com .
About Spiroflow
Spiroflow is a global leader in the field of powder handling and dry solids processing and an emerging leader in control systems integration. Throughout the company’s 50-plus-year history, its design engineers and process automation teams have provided customers with the safest, most efficient, and most reliable conveying and handling solutions available. Learn more at www.spiroflow.com .
About Cablevey Conveyors
Cablevey Conveyors is a global specialty conveyor manufacturer that designs, engineers, assembles and services tubular drag cable and disc conveyor systems. With customers in more than 65 countries, the company specializes in moving materials for food/beverage and industrial powder processors that seek food-grade conveying performance with systems that are clean, fast, energy-efficient and cost-effective. Learn more at www.cablevey.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005971/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
